| abstract |
What is described in this disclosure is that preeclampsia and related conditions (eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, left ventricular dysfunction, and heart failure in pregnant or postpartum women Substances and methods for predicting and / or monitoring). More specifically, the use of the endogenous protein galectin-3 in the prediction and / or monitoring of preeclampsia and related conditions in pregnant or postpartum women is described. Further described are methods for preventing and / or treating preeclampsia and related conditions by inhibiting galectin-3. |